11:09 AM EST, 12/09/2024 (MT Newswires) -- GSK (GSK) said Monday its Blenrep, in combination with bortezomib plus dexamethasone, as a therapy for relapsed or refractory multiple myeloma has been accepted for priority review in China.

The National Medical Products Administration's acceptance marks the seventh major regulatory filing for Blenrep this year, GSK said.

In a filing to the US Securities and Exchange Commission, GSK noted that the application is based on interim findings from the phase 3 trial, which met its primary and secondary endpoints, demonstrating significant improvements in progression-free survival and overall survival compared to the standard of care.

Shares of GSK were up 3.2% in recent trading.

Price: 35.69, Change: +1.12, Percent Change: +3.23